Universiti Sains Malaysia
Kota Bharu, Malaysia
NCT Number: NCT01863251
To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Kota Bharu, Malaysia
The Specific Aims of the proposed study are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Stratera
Time frame: 4 months
The primary evaluation of the effect size in the proposed study will be based on the overall proportions of urine tests negative for ATS and days per month abstinent from ATS use during the 16 week active study period.
Time frame: 4 months
treatment retention
Time frame: 4 months
Reductions in HIV Risk Behaviors, as assessed by computer-assisted self-report inventory
Time frame: 4 months
changes in functional outcomes (assessed by the ASI).
Yale University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00842036
Alcohol Dependence, Alcohol-Related Disorders
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03718065
Chemically-Induced Disorders, Mental Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT03527485
Chemically-Induced Disorders, Cocaine Dependence
New Haven, Connecticut, United States
View Trial DetailsNCT03769025
Chemically-Induced Disorders, Mental Disorders
Philadelphia, Pennsylvania, United States
View Trial Details